|Articles|August 15, 2004

Visual loss of amaruosis fugax can be diagnosed in office

New York-Differentiating the classic embolic visual loss of amaurosis fugax from the numerous other causes of transient visual loss involves careful evaluation. Mark J. Kupersmith, MD, described how to differentiate among the various causes of transient visual disturbance and target the necessary diagnostic procedures.

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!

Latest CME

Multimedia

(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Mitch Ibach, OD, FAAO; Jessica Steen, OD, FAAO

$(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery$

Visual loss of amaruosis fugax can be diagnosed in office

Newsletter

Related Content

Development of maculopathy associated with systemic medications

Throwback Series: When tools of the past teach new lessons

Proactive strategies and sustained delivery advance glaucoma care

STAAR postpones Alcon merger vote, Broadwood calls for removal of board members

Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS

Latest CME

(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Expert Perspectives on Technological Advances in Cataract Surgery

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

EnVision Summit

(CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

Practical Approaches to Modern Dry Eye Treatment and Management

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

20th Annual Controversies in Modern Eye Care

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Collaborative Care Symposium

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment

Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study

STAAR postpones Alcon merger vote, Broadwood calls for removal of board members